Carragelose® Eyedrops
Dry Eye Disease (DED)
Commercial (Out-licensing)Active
Key Facts
Indication
Dry Eye Disease (DED)
Phase
Commercial (Out-licensing)
Status
Active
Company
About Unither Pharmaceuticals
Unither Pharmaceuticals is a global leader in contract manufacturing for liquid pharmaceuticals, with a dominant position in Blow-Fill-Seal (BFS) technology producing over 5 billion doses annually. The company operates nine production sites across four continents, offering comprehensive CDMO services from development to regulatory support and commercial production. With over 2,500 employees, Unither serves a broad client base from startups to large pharma, focusing on therapeutic areas like ophthalmology, ENT, and respiratory diseases. Its business model is built on flexible partnerships including contract manufacturing, co-development, and out-licensing of turnkey products.
View full company profileTherapeutic Areas
Other Dry Eye Disease (DED) Drugs
| Drug | Company | Phase |
|---|---|---|
| Licaminlimab (OCS-02) | Oculis | Phase 2/3 |
| PRP/Excipient Formulation | ECI Therapeutics | Pre-clinical |
| ALG-1007 | Allegro Ophthalmics | Pre-clinical/Phase 1 |
| SLG-100 | Selagine | Clinical Stage (Pilot trial completed) |
| RO-7071759 | Rohto Pharmaceutical | Phase 2 |
| Urcosimod (OK-101) | OKYO Pharma | Phase 2 |